The medicine contains the active substance Ganirelix and belongs to a group of drugs called “gonadotropin-releasing hormone antagonists,” which inhibit the action of natural gonadotropin-releasing hormone (GnRH). GnRH regulates the release of gonadotropins (luteinizing hormones). [LH] and follicle-stimulating hormone [FSH]. Gonadotropins play an important role in human fertility and reproduction. In women, FSH is responsible for the growth and development of egg sacs (follicles) in the ovaries. Follicles are small, round sacs. which contain eggs. LH is necessary for the release of mature eggs from the follicles and ovaries (ovulation). The medicine prevents the action of GnRH, which especially inhibits the release of LH.
The medicine is administered.
- Women undergoing artificial insemination (assisted reproduction), including in vitro fertilization (IVF) and other methods, may sometimes experience early ovulation, which leads to a significantly reduced chance of becoming pregnant. The medicine is used to prevent a premature surge of LH and, therefore, early ovulation.
- In clinical studies, the drug was used with recombinant follicle-stimulating hormone (FSH) or corifollitropin alfa — long-acting follicle stimulator.
